IAG Partners with Leading Academics to Provide AI-powered MRI Analysis of Scleroderma

Image Analysis Group, has established itself as a leading expert in imaging biomarkers for scleroderma and autoimmune diseases through a strategic partnership with the University of Leeds. This collaboration highlights IAG’s commitment to advancing research and clinical trials in these challenging areas:

1. Innovative Imaging Biomarker: IAG and Leeds researchers have developed DAVIX (Digital Artery Volume Index), a novel MRI-based technique for quantifying digital artery volume without contrast agents. This tool offers a more precise assessment of vascular changes in scleroderma patients.

2. AI-Powered Analysis: IAG is applying state-of-the-art machine learning to create an operator-independent tool for scleroderma image quantification, enhancing the reliability and feasibility of scleroderma MRIs.

3. Integration with DYNAMIKA: The new imaging tool will be incorporated into IAG’s proprietary cloud platform DYNAMIKA, streamlining data management and analysis for clinical trials.

4. Market Potential: With the global scleroderma diagnostics and therapeutics market projected to reach $3,663.7 million by 2024, IAG is well-positioned to support pharmaceutical companies in developing and testing new treatments.

5. Validation for Clinical Use: The partnership aims to meet OMERACT (Outcome Measure in Rheumatology Consortium) criteria, potentially establishing DAVIX as a standardized outcome measure for international clinical trials.

By leveraging this advanced imaging technology and expertise, IAG offers pharmaceutical companies developing treatments for scleroderma and other autoimmune diseases a powerful tool to accelerate clinical trials, improve patient stratification, and provide earlier, more accurate assessments of treatment efficacy.